Medicare AdvantageAdministrativeLow impact
Signifor® (pasireotide) (Revised)
Humana·Endocrinology·Medicare Advantage
Effective date
Feb 25, 2026
We identified it
Jun 25, 2026
Summary
Humana has revised its Signifor (pasireotide) prior authorization policy for Medicare Advantage members with Cushing's disease. The policy maintains existing approval criteria requiring diagnosis of Cushing's disease, documented failure or unsuitability of pituitary surgery, and absence of severe hepatic impairment. This 1-day-old revision (effective February 25, 2026) reflects a routine policy update with no material changes to coverage requirements or billing processes.
Action Required
Before February 25, 2026: Billing team should verify that current prior authorization workflows for Signifor (pasireotide) align with the three approval criteria: (1) confirmed Cushing's disease diagnosis, (2) documentation that pituitary surgery is not an option or was not curative, and (3) confirmation of no severe hepatic impairment (Child-Pugh C). No changes to billing codes, submission processes, or documentation requirements are indicated. This is a routine policy revision with no substantive coverage changes.